Sasan Sabrdaran

Dr. Sasan Sabrdaran is a subject matter expert in the field of drug safety, pharmacovigilance and risk management. For more than 16 years, he has been providing his expertise and leadership in both investigational and marketed drugs and has been directly or indirectly involved in design, execution, monitoring, assessment and reporting of more than 70 clinical trials. He has worked for or consulted with both small and global pharmaceutical and biotechnology companies like Genentech, GSK, Pfizer, Shire, Johnson & Johnson, InterMune and many others and has held numerous critical positions of varying responsibilities in those companies. Among his many contributions to the science of medicine, his most notable success is his contribution as a Senior Drug Safety Scientist at Genentech to bringing the breakthrough drugs Avastin, the best anti-cancer treatment in the world, and Xolair, the first-in-class anti-IgA for treatment of Allergic Asthma to the market. He has also been the Senior Director of Drug Safety Risk Management at InterMune, where he was the lead safety physician and the primary architect of the global risk management strategies and safety surveillance activities for Esbriet, the first treatment for IPF, which received the regulatory approval in Europe and ultimately in the United States. Dr. Sabrdaran has authored, reviewed and/or approved over 10,000 Individual Case Safety Reports from clinical trial and post marketing sources and over 50 aggregate safety analyses and plan including PSURs, ASRs, Risk Management Plans, IND Annual Reports and DSURs and had written numerous responses to Health Authority inquiries on various drug safety issues.